Sarilumab tops Humira in RA Phase III

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Sanofi (Euronext:SAN; NYSE:SNY) said sarilumab ( REGN88, SAR153191) met the primary endpoint of superiority to Humira adalimumab from AbbVie Inc. (NYSE:ABBV) in the Phase III SARIL-RA-MONARCH trial to treat rheumatoid arthritis.

Bi-weekly subcutaneous sarilumab, a human mAb against the IL-6 receptor, was superior to Humira in improving signs and symptoms in patients with active RA as measured by the change from baseline in disease activity score using erythrocyte sedimentation rate (DAS28-ESR) at week 24 (p<0.0001). ...